Adebrelimab
- Generic Name
- Adebrelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06465563
- Locations
- 🇨🇳
The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
- Conditions
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Target Recruit Count
- 54
- Registration Number
- NCT06464614
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 216
- Registration Number
- NCT06455410
- Locations
- 🇨🇳
Affiliated cancer hospital and institute of guangzhou medical university, Guangzhou, China
🇨🇳The affiliated panyu central hospital of guangzhou medical university, Guangzhou, China
🇨🇳Liuzhou Workers Hospital, Liuzhou, China
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06439589
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Beijing GoBroad Hospital
- Target Recruit Count
- 131
- Registration Number
- NCT06433609
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 35
- Registration Number
- NCT06427239
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Zeng Jian
- Target Recruit Count
- 92
- Registration Number
- NCT06424899
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06418594
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-29
- Target Recruit Count
- 30
- Registration Number
- NCT06415669
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Fuzhou, Fujian, China
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-07-15
- Target Recruit Count
- 40
- Registration Number
- NCT06405061
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
🇨🇳Third Central Hospital of Tianjin, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.